- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01548391
A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects
March 7, 2012 updated by: Biotoxtech Co., Ltd
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of HX-1171 in healthy male subjects.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
66
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Contact:
- Kyun-Seop Bae, M.D., Ph.D.
- Phone Number: 82-2-3010-4611
- Email: ksbae@amc.seoul.kr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Adult males aged 20 to 40 years at screening.
- Be able to comply with the requirement of the study. Subject must provide written informed consent prior to study participation.
Exclusion Criteria:
- History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or gastrointestinal disorders.
- History of known hypersensitivity to drugs including HX-1171.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HX-1171 20 mg (20mg 1T)
|
20mg, 200mg, 500mg
|
Experimental: HX-1171 40 mg (20mg 2T)
|
20mg, 200mg, 500mg
|
Experimental: HX-1171 80 mg (20mg 4T)
|
20mg, 200mg, 500mg
|
Experimental: HX-1171 160 mg (20mg 8T)
|
20mg, 200mg, 500mg
|
Experimental: HX-1171 300 mg (200mg 1T, 20mg 5T)
|
20mg, 200mg, 500mg
|
Experimental: HX-1171 600 mg (200mg 3T)
|
20mg, 200mg, 500mg
|
Experimental: HX-1171 1200 mg (500mg 2T, 200mg 1T)
|
20mg, 200mg, 500mg
|
Experimental: HX-1171 1500 mg (500mg 3T)
|
20mg, 200mg, 500mg
|
Experimental: HX-1171 2000 mg (500mg 4T)
|
20mg, 200mg, 500mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (normal results for safety tests)
Time Frame: 14days
|
Physical examination, Vital signs
|
14days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Study Registration Dates
First Submitted
March 5, 2012
First Submitted That Met QC Criteria
March 7, 2012
First Posted (Estimate)
March 8, 2012
Study Record Updates
Last Update Posted (Estimate)
March 8, 2012
Last Update Submitted That Met QC Criteria
March 7, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Other Study ID Numbers
- 2012-0070
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on HX-1171
-
Biotoxtech Co., LtdTemporarily not available
-
Onconova Therapeutics, Inc.Recruiting
-
Istituto Nazionale Assicurazione contro gli Infortuni...Scuola Superiore Sant'Anna di PisaCompleted
-
Maastricht Radiation OncologyAmsterdam UMC, location VUmcCompleted
-
Greater Baltimore Medical CenterWithdrawnCancer | Patients With Clinical and Environmental Risk Factors for Cancer | Patients With a Suspected or Confirmed Diagnosis of CancerUnited States
-
Evofem Inc.Johns Hopkins University; MetroHealth Medical Center; Clinical Research Management...Completed
-
University of CambridgeNorfolk and Norwich University Hospitals NHS Foundation Trust; Barts & The... and other collaboratorsRecruiting
-
University of CambridgeCambridge University Hospitals NHS Foundation TrustCompleted
-
University of CambridgeUniversity Hospital Inselspital, BerneCompletedEnd Stage Renal Disease | Type 2 DiabetesUnited Kingdom, Switzerland
-
Lia BallyUniversity Hospital, Basel, SwitzerlandCompletedLiver Diseases | Diabetes Mellitus, Type 2 | Gastric Disease | Colon Disease | Insulin Therapy | Pancreatic Disease | Perioperative Hyperglycaemia | Elective Surgery | Closed-Loop Glucose Control | Artificial PancreasSwitzerland